Valuation: GlaxoSmithKline plc

Market Cap 7.81TCr 10TCr 9.15TCr 8.44TCr 15TCr 9,98500Cr 15TCr 1,01100Cr 40TCr 4,90300Cr 39TCr 38TCr 16,98400Cr P/E 2026 *
12.5x
P/E 2027 * 11.4x
Enterprise Value 9.34TCr 13TCr 11TCr 10TCr 18TCr 11,94000Cr 18TCr 1,20900Cr 47TCr 5,86400Cr 47TCr 46TCr 20,31000Cr EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.54x
Free-Float
92.29%
Yield 2026 *
3.56%
Yield 2027 * 3.74%
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.25%+54.65%+168.55% 1,08400Cr
-1.63%-1.50%+65.79%+62.43% 63TCr
-1.12%-4.27%+31.10%+85.82% 45TCr
+0.18%+2.04%+30.19%+26.51% 33TCr
-6.22%-3.61%+29.15%+32.09% 30TCr
-1.27%-0.56%+27.21%+46.39% 28TCr
-0.93%-1.19%-28.85%-40.38% 22TCr
-1.19%-2.81%+22.63%+61.80% 20TCr
-0.72%+2.72%+19.07%+78.15% 17TCr
Average -1.43%+2.52%+27.88%+57.93% 40.67TCr
Weighted average by Cap. -1.11%+2.48%+38.96%+84.35%

Financials

2026 *2027 *
Net sales 3.39TCr 4.54TCr 3.97TCr 3.66TCr 6.43TCr 4,33100Cr 6.53TCr 44TCr 17TCr 2,12700Cr 17TCr 17TCr 7,36600Cr 3.56TCr 4.77TCr 4.17TCr 3.85TCr 6.76TCr 4,55100Cr 6.87TCr 46TCr 18TCr 2,23500Cr 18TCr 18TCr 7,74200Cr
Net income 650.49Cr 871.48Cr 762.38Cr 703.04Cr 1.23TCr 83TCr 1.26TCr 8.42TCr 3.3TCr 41TCr 3.27TCr 3.2TCr 1,41500Cr 703.67Cr 942.73Cr 824.7Cr 760.51Cr 1.34TCr 90TCr 1.36TCr 9.11TCr 3.57TCr 44TCr 3.54TCr 3.46TCr 1,53100Cr
Net Debt 1.53TCr 2.05TCr 1.79TCr 1.65TCr 2.9TCr 1,95600Cr 2.95TCr 20TCr 7.76TCr 96TCr 7.69TCr 7.52TCr 3,32600Cr 1.22TCr 1.64TCr 1.43TCr 1.32TCr 2.32TCr 1,56400Cr 2.36TCr 16TCr 6.21TCr 77TCr 6.15TCr 6.02TCr 2,66100Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-